UPMC Enterprises

UPMC Enterprises develops and invests in technology aimed at solving complex problems in health care. It is the innovation, commercialization, and venture capital arm of UPMC, a health care provider and insurer based in Pittsburgh, PA. The organization provides its portfolio companies and partners with capital, connections, and resources, and focuses on two areas: Translational Sciences and Digital Solutions. It also offers technology services including Ahavi™ data and analytics, strategic services, infrastructure and security services, and product acceleration services.

UPMC Enterprises is the innovation, commercialization, and venture capital arm of UPMC, a $28 billion health care provider and insurer based in Pittsburgh, PA. It develops and invests in technology that is helping to solve some of the hardest and most complex problems in health care. The organization taps the clinical acumen of more than 5,000 UPMC physicians and relies on payer perspectives from the UPMC Health Plan, which provides affordable, high-quality, value-based care to more than 4 million members. It invests financial and intellectual capital into developing solutions that benefit the entire health care industry, supporting both early and growth stage companies. When it invests in or forms a company, the Enterprises team becomes an integral part of that company, offering far more than just financial capital.

Innovation, commercialization, and venture capital arm of UPMC focused on health care technology.

• Ahavi™

  A real-world data platform developed by UPMC Enterprises to provide de-identified health care data to enable researchers, scientists, and developers to create curated datasets for accelerating research, clinical trial design, and AI development.

• 2021.08.05

  Reported2021.08.05

  Smile CDR closes $20 million Series A funding[5]Smile CDR完成2,000万美元A轮融资prnewswire.com

  Smile CDR announced that it had closed $20 million in Series A growth capital led by 30 North Group and UPMC Enterprises.

• 2021.06.15

  Reported2021.06.15

  Sempre Health closes $15 million Series B financing[6]Sempre Health完成1500万美元B轮融资prnewswire.com

  Sempre Health announced the closing of a $15 million Series B financing to advance its network of payors and pharmaceutical manufacturers nationwide and expand the number of patients it can serve.

• 2020.10.21

  Reported2020.10.22

  SparingVision announces €44.5 million financing[7]SparingVision 宣布融资 4,450 万欧元biospace.com

  SparingVision announced a €44.5 million financing round led by 4BIO Capital and UPMC Enterprises, with Ysios Capital and existing investors also participating.

• 2019.11.20

  Reported2019.11.20

  Werewolf Therapeutics completes $56 million Series A financing[8]Werewolf Therapeutics 完成 5600 万美元 A 轮融资prnewswire.com

  Werewolf Therapeutics announced completion of a $56 million Series A financing led by MPM Capital and Longwood Fund, with four other investors joining the round.

Read more

1. 1Home | UPMC Enterprisesenterprises.upmc.com
2. 2Technology Services | UPMC Enterprisesenterprises.upmc.com
3. 3Ahavi | UPMC Enterprisesenterprises.upmc.com
4. 4About | UPMC Enterprisesenterprises.upmc.com
5. 5Smile CDR完成2,000万美元A轮融资prnewswire.com
6. 6Sempre Health完成1500万美元B轮融资prnewswire.com
7. 7SparingVision 宣布融资 4,450 万欧元biospace.com
8. 8Werewolf Therapeutics 完成 5600 万美元 A 轮融资prnewswire.com